Prescription patterns and costs of acne/rosacea medications in Medicare patients vary by prescriber specialty - 12/08/17
Abstract |
Background |
Prescription patterns for acne/rosacea medications have not been described in the Medicare population, and comparisons across specialties are lacking.
Objective |
To describe the medications used for treating acne/rosacea in the Medicare population and evaluate differences in costs between specialties.
Methods |
A cross-sectional study was performed of the 2008 and 2010 Centers for Medicare and Medicaid Services Prescription Drug Profiles, which contains 100% of Medicare part D claims.
Results |
Topical antibiotics accounted for 63% of all prescriptions. Patients ≥65 years utilized more oral tetracycline-class antibiotics and less topical retinoids. Specialists prescribed brand name drugs for the most common topical retinoids and most common topical antibiotics more frequently than family medicine/internal medicine (FM/IM) physicians by 6%-7%. Topical retinoids prescribed by specialists were, on average, $18-$20 more in total cost and $2-$3 more in patient cost than the same types of prescriptions from FM/IM physicians per 30-day supply. Specialists (60%) and IM physicians (56%) prescribed over twice the rate of branded doxycycline than FM doctors did (27%). The total and patient costs for tetracycline-class antibiotics were higher from specialists ($18 and $4 more, respectively) and IM physicians ($3 and $1 more, respectively) than they were from FM physicians.
Limitations |
The data might contain rare prescriptions used for conditions other than acne/rosacea, and suppression algorithms might underestimate the number of specialist brand name prescriptions.
Conclusion |
Costs of prescriptions for acne/rosacea from specialists are higher than those from primary care physicians and could be reduced by choosing generic and less expensive options.
Le texte complet de cet article est disponible en PDF.Key words : acne, antibiotics, cost of care, Medicare, prescription drug costs, rosacea, topical retinoids
Abbreviations used : FM, IM, TCA
Plan
Funding sources: Supported by the Agency for Healthcare Research and Quality (grant number K12 HS023011) and the Dermatology Foundation (Dr Silverberg). |
|
Conflicts of interest: Dr Kaffenberger serves on the advisory board of Castle Biosciences and has received research funds from Eli Lilly, XBiotech, Celgene, and Biogen. Mr Zhang and Dr Silverberg have no conflicts of interest to report. |
Vol 77 - N° 3
P. 448 - septembre 2017 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?